DLL4/NOTCH1/PPARγ agonists and/or PI3K/AKT antagonists are attractive therapeutic targets for preventing or even possibly reversing progressive pathologic vasculopathy in PAH. This evidence concerns the gene DLL4 and vascular disorder.